Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received approval for a clinical trial of their innovative drug, SKB500, aimed at treating advanced solid tumors. This novel ADC drug, developed using the OptiDC platform, has shown promising preclinical results. Investors are advised to exercise caution as the drug’s development and commercialization are not guaranteed.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.